Stephen Hoffman, CEO of Aerpio Pharmaceuticals, reviews the development of the small-molecule, systemic agent AKB-9778 in two important areas of ocular disease: proliferative diabetic retinopathy and glaucoma. REGISTER for our next ophthalmology conference today [ Ссылка ].

WEBSITE
[ Ссылка ]

FOLLOW Ophthalmology Innovation Summit On Social Media:
► Facebook: [ Ссылка ]
► Twitter: [ Ссылка ]

JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn
[ Ссылка ]

SUBSCRIBE To Our Weekly OIS Newsletter
[ Ссылка ]

VIEW Our Past Ophthalmology Event Conferences:
[ Ссылка ]

REGISTER For Our Next Conference:
[ Ссылка ]

#OIS #Ophthalmology #Healthcare

_________________________________________________________________

About OIS

Ophthalmology Innovation Summit, or OIS for short, facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.

The Ophthalmology Innovation Summit programs are presented annually by Healthegy, Inc. as affiliate meetings with American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Southeastern Congress of Optometry (SECO), and American Society of Retina Specialists (ASRS).

____________________________________________________________________

Healthegy also is the producer of Aesthetics Innovation Summit (AIS), which unites the clinical, corporate and capital leaders to facilitate the exchange of insights on emerging trends while showcasing exciting new drugs, devices, and technologies for the aesthetics market which is projected to double by 2025.

► Website: [ Ссылка ]
► Facebook: [ Ссылка ]
► Instagram: [ Ссылка ]
► Twitter: [ Ссылка ]
► Healthegy Website: [ Ссылка ]

свернуть